Table 4.

FGFR3IIIb and FGFR3IIIc Expression in Esophageal Carcinoma (EC) and Non-Cancerous Mucosa (NCM).

	FGFR3IIIb Expression		FGFR3IIIc Expression
	NCM (N)	EC (T)	NCM (N)	EC (T)
Stage of ESCC Patients (n=14)
I	5/5 (100%)	3/5 (60%)	4/5 (80%)	3/5 (60%)
II	1/1 (100%)	1/1 (100%)	0/1 (0%)	1/1 (100%)
III	4/7 (57%)	6/7 (86%)	1/7 (14%)	6/7 (86%)
IV	1/1 (100%)	1/1 (100%)	1/1 (100%)	1/1 (100%)
Stage of EAC Patients (n=2)
III	0/2 (0%)	1/2 (50%)	0/2 (0%)	1/2 (50%)
Incidence of all patients (n=16)	11/16 (69%)	12/16 (75%) (p=1)	6/16 (38%)	12/16 (75%) (p=0.073)

ESCC, Esophageal squamous cell carcinoma; EAC, Adenocarcinoma; T, tumor; N, non-tumor; p<0.05 versus the NCM; Fisher’s exact test.